{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:08:31Z","timestamp":1777417711327,"version":"3.51.4"},"reference-count":119,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2002,5]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>Citations obtained from MEDLINE searches (1985\u2013September 2001) using lamotrigine as a text word, articles identified in reference lists of pertinent articles, abstracts presented at conferences, and research data from GlaxoSmithKline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA EXTRACTION:<\/jats:title>\n                    <jats:p>English-language articles were considered for possible inclusion. Each title and abstract was examined to determine whether the publication contained up-to-date information relevant to the objective. Twenty clinical trials that provided data on response rates in mood disorders were tabulated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:<\/jats:title>\n                    <jats:p>Lamotrigine's primary action is to modulate voltage-gated sodium channels. Evidence suggests that it decreases glutamate transmission, directly reduces calcium influx, mildly blocks transmitter reuptake, and alters intracellular mechanisms of resting transmitter release. The average half-life of lamotrigine is approximately 24 hours, but decreases to approximately 7.4 hours when used concurrently with phenytoin, and increases to approximately 59 hours with valproic acid. Seven of the 20 clinical trials were randomized, double-blind, and controlled. Existing data are inadequate to evaluate lamotrigine use in major depression. The pooled response rates for patients with depressed, manic, mixed, and rapid cycling bipolar disorder were similar, ranging from 52% to 63%. Adverse effects are infrequent when the drug is used alone, but become more frequent when lamotrigine is combined with other anticonvulsants. While most rashes are mild, approximately 1 in 500 patients develops exfoliative dermatitis. A slow upward dose titration is recommended to reduce the incidence of serious rash, but this may delay the attainment of adequate dosage for 6 weeks. Lamotrigine has positive effects on cognitive function, but occasionally produces insomnia. Lamotrigine costs 2\u20134 \u00d7 more than lithium, carbamazepine, and generic valproic acid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>When efficacy, adverse effects, and cost are considered, lamotrigine should probably be reserved as a second-line agent for bipolar depression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1a102","type":"journal-article","created":{"date-parts":[[2003,6,4]],"date-time":"2003-06-04T16:20:48Z","timestamp":1054743648000},"page":"860-873","source":"Crossref","is-referenced-by-count":38,"title":["Lamotrigine Update and its Use in Mood Disorders"],"prefix":"10.1177","volume":"36","author":[{"given":"Stephen C","family":"Hurley","sequence":"first","affiliation":[{"name":"Stephen C Hurley PharmD BCPP, Professor of Pharmacy Practice, College of Pharmacy, Idaho State University, Pocatello, ID; Clinical Pharmacist, State Hospital South, 700 E. Alice St., PO Box 400, Blackfoot, ID 83221-0440, FAX 208\/785-8448"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2002,5,1]]},"reference":[{"key":"bibr-bibr1-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.11.1635"},{"key":"bibr-bibr2-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1993.tb02417.x"},{"key":"bibr-bibr3-aph.1A102","unstructured":"Weisler RH. Use of lamotrigine in the treatment of bipolar disorder (abstract). Presented at the Sesquicentennial Annual Meeting of the American Psychiatric Association, Philadelphia, May 21\u201326, 1994."},{"key":"bibr-bibr4-aph.1A102","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199818040-00004"},{"key":"bibr-bibr5-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(92)90065-2"},{"key":"bibr-bibr6-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(00)00051-4"},{"key":"bibr-bibr7-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1159\/000026527"},{"key":"bibr-bibr8-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(95)00104-E"},{"key":"bibr-bibr9-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(96)00265-8"},{"key":"bibr-bibr10-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(199808)29:4<355::AID-SYN7>3.0.CO;2-4"},{"key":"bibr-bibr11-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200107200-00042"},{"key":"bibr-bibr12-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00580-9"},{"key":"bibr-bibr13-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199610000-00001"},{"key":"bibr-bibr14-aph.1A102","first-page":"95","volume":"269","author":"Paul IA","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr-bibr15-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00330-1"},{"key":"bibr-bibr16-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00230-9"},{"key":"bibr-bibr17-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997"},{"key":"bibr-bibr18-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.3.270"},{"key":"bibr-bibr19-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900022008"},{"key":"bibr-bibr20-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1177\/00912709922007949"},{"key":"bibr-bibr21-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1177\/0883073897012001041"},{"key":"bibr-bibr22-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00252.x"},{"key":"bibr-bibr23-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.00594.x"},{"key":"bibr-bibr24-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb04079.x"},{"key":"bibr-bibr25-aph.1A102","first-page":"25","volume":"19","author":"Fillastre JP","year":"1993","journal-title":"Drugs Exp Clin Res"},{"key":"bibr-bibr26-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1995.tb04346.x"},{"key":"bibr-bibr27-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1997.tb00028.x"},{"key":"bibr-bibr28-aph.1A102","first-page":"1169","volume":"289","author":"Furlan V","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr-bibr29-aph.1A102","first-page":"184","volume":"61","author":"De Bony F","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"bibr-bibr30-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1081\/DMR-100101944"},{"key":"bibr-bibr31-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00835.x"},{"key":"bibr-bibr32-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90130-7"},{"key":"bibr-bibr33-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199904000-00006"},{"key":"bibr-bibr34-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000146"},{"key":"bibr-bibr35-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(98)80074-5"},{"key":"bibr-bibr36-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.4.588"},{"key":"bibr-bibr37-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200012000-00003"},{"key":"bibr-bibr38-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(01)00305-9"},{"key":"bibr-bibr39-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00232.x"},{"key":"bibr-bibr40-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199706000-00002"},{"key":"bibr-bibr41-aph.1A102","first-page":"121","volume":"1","author":"Posner J","year":"1991","journal-title":"J Pharm Med"},{"key":"bibr-bibr42-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1159\/000026540"},{"key":"bibr-bibr43-aph.1A102","volume-title":"Diagnostic and statistical manual of mental disorders","year":"1994","edition":"4"},{"key":"bibr-bibr44-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03370220100035"},{"key":"bibr-bibr45-aph.1A102","first-page":"215","volume":"21","author":"Dunn RT","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"bibr-bibr46-aph.1A102","first-page":"23","volume":"1","author":"Anand A","year":"1999","journal-title":"Bipolar Disord"},{"key":"bibr-bibr47-aph.1A102","unstructured":"Berlant JL. Attention deficit hyperactivity disorder and bipolar disorder as predictors of clinical response to lamotrigine (abstract). Presented at: Second Annual International Conference on Bipolar Disorder, Pittsburgh, PA, June 19\u201321, 1997."},{"key":"bibr-bibr48-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00013-X"},{"key":"bibr-bibr49-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1159\/000026535"},{"key":"bibr-bibr50-aph.1A102","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n1106"},{"key":"bibr-bibr51-aph.1A102","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0203"},{"key":"bibr-bibr52-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.7.1019"},{"key":"bibr-bibr53-aph.1A102","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n1202"},{"key":"bibr-bibr54-aph.1A102","unstructured":"Ferrier IN, Potkins D, Eccleston D. Lamotrigine treatment in rapid cycling bipolar disorder: clinical and biological correlates (abstract). Second Annual International Conference on Bipolar Disorder, Pittsburgh, PA, June 19\u201321, 1997."},{"key":"bibr-bibr55-aph.1A102","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n0607b"},{"key":"bibr-bibr56-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200012000-00004"},{"key":"bibr-bibr57-aph.1A102","first-page":"35","volume":"1","author":"Hoopes S","year":"1999","journal-title":"Bipolar Disord"},{"key":"bibr-bibr58-aph.1A102","doi-asserted-by":"publisher","DOI":"10.3109\/10401230009147081"},{"key":"bibr-bibr59-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(97)00082-6"},{"key":"bibr-bibr60-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.8.1171b"},{"key":"bibr-bibr61-aph.1A102","first-page":"39","volume":"1","author":"Lafer B","year":"1999","journal-title":"Bipolar Disord"},{"key":"bibr-bibr62-aph.1A102","unstructured":"Londborg PD, Cutler NR, Cunningham LA, Haines FX, Pahl JJ, West SA,  Lamotrigine in the treatment of unipolar depression (abstract). Presented at: Annual Meeting of the American Psychiatric Association, Washington, DC, May 15\u201320, 1999."},{"key":"bibr-bibr63-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199706000-00008"},{"key":"bibr-bibr64-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00077-9"},{"key":"bibr-bibr65-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2000.020408.x"},{"key":"bibr-bibr66-aph.1A102","volume-title":"Data on file"},{"key":"bibr-bibr67-aph.1A102","first-page":"65","volume":"21","author":"Kotler M","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"bibr-bibr68-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979570"},{"key":"bibr-bibr69-aph.1A102","unstructured":"Berlant JL. Case report of synergistic response of rapid cycling bipolar disorder to lamotrigine, risperidone, and verapamil (abstract). Presented at: Second Annual International Conference on Bipolar Disorder, Pittsburgh, PA, June 19\u201321, 1997."},{"key":"bibr-bibr70-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.9.1236a"},{"key":"bibr-bibr71-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(97)88531-8"},{"key":"bibr-bibr72-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.9.1317a"},{"key":"bibr-bibr73-aph.1A102","first-page":"93S","volume":"42","author":"Mandoki M","year":"1997","journal-title":"Biol Psychiatry"},{"key":"bibr-bibr74-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.11.1833"},{"key":"bibr-bibr75-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006223422506"},{"key":"bibr-bibr76-aph.1A102","volume-title":"Clinical practice guideline, number 5","author":"Depression Guideline Panel","year":"1993"},{"key":"bibr-bibr77-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.6.829"},{"key":"bibr-bibr78-aph.1A102","unstructured":"Frye MA, Ketter TA, Osuch EA, Kimbrell TA, Speer AM, Dunn RM,  Gabapentin and lamotrigine monotherapy in mood disorder: an update (abstract). Presented at: Annual Meeting of the American Psychiatric Association, Toronto, May 30\u2013June 4, 1998."},{"key":"bibr-bibr79-aph.1A102","volume-title":"A one-year study of lamotrigine in patients with bipolar depression (abstract)","author":"Ascher J","year":"2000"},{"key":"bibr-bibr80-aph.1A102","unstructured":"Huffman R, Rudd D, Monaghan E, Ascher J, Womble G, Bowden C,  The safety and efficacy of lamotrigine for the long-term treatment of bipolar depression (abstract). Presented at: Annual Meeting of the American Psychiatric Association, Chicago, May 13\u201318, 2000."},{"key":"bibr-bibr81-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199911000-00003"},{"key":"bibr-bibr82-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01251.x"},{"key":"bibr-bibr83-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.4.973"},{"key":"bibr-bibr84-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00807.x"},{"key":"bibr-bibr85-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01252.x"},{"key":"bibr-bibr86-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00831.x"},{"key":"bibr-bibr87-aph.1A102","first-page":"S164","volume":"37","author":"Manasco P","year":"1996","journal-title":"Epilepsia"},{"key":"bibr-bibr88-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1989.tb01220.x"},{"key":"bibr-bibr89-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.2000.0394"},{"key":"bibr-bibr90-aph.1A102","volume-title":"Lamictal (lamotrigine)","year":"2000"},{"key":"bibr-bibr91-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2000.19107"},{"key":"bibr-bibr92-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005593119425"},{"key":"bibr-bibr93-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1345\/aph.18422"},{"key":"bibr-bibr94-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1017\/S0012162299220130"},{"key":"bibr-bibr95-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.12.2015"},{"key":"bibr-bibr96-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.2.542"},{"key":"bibr-bibr97-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)05418-X"},{"key":"bibr-bibr98-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512143332404"},{"issue":"5","key":"bibr-bibr99-aph.1A102","first-page":"S53","volume":"53","author":"Ketter TA","year":"1999","journal-title":"Neurology"},{"key":"bibr-bibr100-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.2.321"},{"key":"bibr-bibr101-aph.1A102","first-page":"41","volume":"21","author":"Marciani MG","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"bibr-bibr102-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.170.4.388b"},{"key":"bibr-bibr103-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1177\/0883073897012001101"},{"key":"bibr-bibr104-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1080\/02699050050191931"},{"key":"bibr-bibr105-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2000.102002081.x"},{"key":"bibr-bibr106-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00712.x"},{"key":"bibr-bibr107-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00271.x"},{"key":"bibr-bibr108-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01373.x"},{"key":"bibr-bibr109-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01183.x"},{"key":"bibr-bibr110-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.7.1178"},{"key":"bibr-bibr111-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199710000-00002"},{"key":"bibr-bibr112-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03122.x"},{"key":"bibr-bibr113-aph.1A102","first-page":"35","volume":"19","author":"Shaw SC","year":"2000","journal-title":"Adverse Drug React Toxicol Rev"},{"key":"bibr-bibr114-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb06044.x"},{"key":"bibr-bibr115-aph.1A102","unstructured":"Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The expert consensus guideline series: Medication treatment of bipolar disorder 2000. Postgrad Med 2000;spec no:1\u2013104. (also available from: URL: http:\/\/www.psychguides.com\/gl-treatment_of_bp2000.html)."},{"key":"bibr-bibr116-aph.1A102","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n1102"},{"key":"bibr-bibr117-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1159\/000054845"},{"key":"bibr-bibr118-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.157.1.124"},{"key":"bibr-bibr119-aph.1A102","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.2000.0428"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1A102","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1A102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:05:35Z","timestamp":1777374335000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1A102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":119,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["10.1345\/aph.1A102"],"URL":"https:\/\/doi.org\/10.1345\/aph.1a102","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5]]}}}